| Gilbert Perkins Klemann, MD | |
|
5050 Ne Hoyt St Ste 514, Portland, OR 97213-2984 | |
| (503) 488-2323 | |
| (503) 488-2340 |
| Full Name | Gilbert Perkins Klemann |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 22 Years |
| Location | 5050 Ne Hoyt St Ste 514, Portland, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679629927 | NPI | - | NPPES |
| 247523 | Medicaid | OR | |
| 8476020 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | MD27214 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Portland Medical Center | Portland, OR | Hospital |
| Providence Willamette Falls Medical Center | Oregon city, OR | Hospital |
| Legacy Good Samaritan Medical Center | Portland, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Oregon Clinic Pc | 2860390408 | 319 |
News Archive
Cardium Therapeutics today announced the initiation of the ASPIRE Phase 3 registration study to evaluate the therapeutic effects of Cardium's lead product candidate, Generx (Ad5FGF-4) in patients with myocardial ischemia.
FibroGen, Inc., today announced that new data from a phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia will be presented demonstrating that its first-in-class, investigational oral anemia therapy FG-4592 works differently than erythropoiesis stimulating agents (ESAs) to increase hemoglobin.
Pfenex today announced that Science Applications International Corporation has awarded Pfenex a sub-contract valued at $3.1 million to help develop a robust, scalable, cGMP ready production process for large scale production of full length Circumsporozoite protein from Plasmodium falciparum.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma and refractory advanced colorectal cancer.
› Verified 8 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003991845 PECOS PAC ID: 5395656284 Enrollment ID: O20031113000626 |
News Archive
Cardium Therapeutics today announced the initiation of the ASPIRE Phase 3 registration study to evaluate the therapeutic effects of Cardium's lead product candidate, Generx (Ad5FGF-4) in patients with myocardial ischemia.
FibroGen, Inc., today announced that new data from a phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia will be presented demonstrating that its first-in-class, investigational oral anemia therapy FG-4592 works differently than erythropoiesis stimulating agents (ESAs) to increase hemoglobin.
Pfenex today announced that Science Applications International Corporation has awarded Pfenex a sub-contract valued at $3.1 million to help develop a robust, scalable, cGMP ready production process for large scale production of full length Circumsporozoite protein from Plasmodium falciparum.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma and refractory advanced colorectal cancer.
› Verified 8 days ago
| Entity Name | Oregon Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265417174 PECOS PAC ID: 2860390408 Enrollment ID: O20031222000096 |
News Archive
Cardium Therapeutics today announced the initiation of the ASPIRE Phase 3 registration study to evaluate the therapeutic effects of Cardium's lead product candidate, Generx (Ad5FGF-4) in patients with myocardial ischemia.
FibroGen, Inc., today announced that new data from a phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia will be presented demonstrating that its first-in-class, investigational oral anemia therapy FG-4592 works differently than erythropoiesis stimulating agents (ESAs) to increase hemoglobin.
Pfenex today announced that Science Applications International Corporation has awarded Pfenex a sub-contract valued at $3.1 million to help develop a robust, scalable, cGMP ready production process for large scale production of full length Circumsporozoite protein from Plasmodium falciparum.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma and refractory advanced colorectal cancer.
› Verified 8 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366536963 PECOS PAC ID: 6103728753 Enrollment ID: O20040123000371 |
News Archive
Cardium Therapeutics today announced the initiation of the ASPIRE Phase 3 registration study to evaluate the therapeutic effects of Cardium's lead product candidate, Generx (Ad5FGF-4) in patients with myocardial ischemia.
FibroGen, Inc., today announced that new data from a phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia will be presented demonstrating that its first-in-class, investigational oral anemia therapy FG-4592 works differently than erythropoiesis stimulating agents (ESAs) to increase hemoglobin.
Pfenex today announced that Science Applications International Corporation has awarded Pfenex a sub-contract valued at $3.1 million to help develop a robust, scalable, cGMP ready production process for large scale production of full length Circumsporozoite protein from Plasmodium falciparum.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma and refractory advanced colorectal cancer.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gilbert Perkins Klemann, MD 541 Ne 20th Ave Ste 225, Portland, OR 97232-2895 Ph: (503) 963-2801 | Gilbert Perkins Klemann, MD 5050 Ne Hoyt St Ste 514, Portland, OR 97213-2984 Ph: (503) 488-2323 |
News Archive
Cardium Therapeutics today announced the initiation of the ASPIRE Phase 3 registration study to evaluate the therapeutic effects of Cardium's lead product candidate, Generx (Ad5FGF-4) in patients with myocardial ischemia.
FibroGen, Inc., today announced that new data from a phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia will be presented demonstrating that its first-in-class, investigational oral anemia therapy FG-4592 works differently than erythropoiesis stimulating agents (ESAs) to increase hemoglobin.
Pfenex today announced that Science Applications International Corporation has awarded Pfenex a sub-contract valued at $3.1 million to help develop a robust, scalable, cGMP ready production process for large scale production of full length Circumsporozoite protein from Plasmodium falciparum.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma and refractory advanced colorectal cancer.
› Verified 8 days ago
Donald Andrew Young Iii, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 5050 Ne Hoyt St, Suite 514, Portland, OR 97213 Phone: 503-488-2323 Fax: 503-488-2340 | |
Dr. James Christopher Austin, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Pediatric Urology Cdw-6, Portland, OR 97239 Phone: 503-494-4808 Fax: 503-494-4743 | |
Lauren Lamina, Urology Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Portland, OR 97239 Phone: 503-494-8311 | |
Dr. Jin-hee Kim, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 10000 Se Main St, Ste 342, Portland, OR 97216 Phone: 503-255-5244 Fax: 503-255-5120 | |
Michael Joseph Conlin, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 3303 Sw Bond Ave, Ch10u, Portland, OR 97239 Phone: 503-494-4779 Fax: 503-494-8671 | |
Dr. James M Keane, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 9155 Sw Barnes Rd, Ste 422, Portland, OR 97225 Phone: 503-297-1078 Fax: 503-292-2176 | |
Marshall Strother, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 3303 S Bond Ave, Portland, OR 97239 Phone: 503-346-1500 Fax: 503-494-8671 |